US clearance lifts Glaxo-Wellcome

US clearance lifts Glaxo-Wellcome

Glaxo-Wellcome share price was buoyed yesterday by news that the company has received clearance by the United States Food and Drug Administration to market the tablet form of Imitrex, its migraine treatment. The drug has previously been available as an injection. The shares had been hit earlier in the day by press reports that a US broker had said the shares were overvalued.